AMRUTANJAN vs VENUSREM: Stock Comparison
VENUSREM is the larger company by market capitalisation. AMRUTAJAN HEALTH shows a higher ROE, a higher dividend yield and a higher ROCE, while VENUSREM shows a lower P/E, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AMRUTANJAN leads 4; VENUSREM leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AMRUTANJAN | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AMRUTANJAN | VENUSREM |
|---|---|---|
| Live Price | ₹487.65 | ₹1,796.7 |
| Day Change | -1.88% | 0.03% |
| Volume | 35,012 | 1.17 L |
| 52-Week High | ₹760.15 | ₹1,880 |
| 52-Week Low | ₹476.5 | ₹432.1 |
| Distance from 52W High | -35.85% | -4.43% |
Valuation
| Metric | AMRUTANJAN | VENUSREM |
|---|---|---|
| Market Cap | ₹1,408 Cr | ₹1,898 Cr |
| P/E Ratio | 26.57x | 16.56x |
| P/B Ratio | 3.87x | 2.9x |
| EPS | ₹18.67 | ₹17.18 |
| Book Value | ₹128.04 | ₹496.56 |
| Dividend Yield | 1.51% | 0.69% |
Growth
| Metric | AMRUTANJAN | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 10.5% | 33% |
| EPS Growth (TTM YoY) | 6.7% | 126.4% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | AMRUTANJAN | VENUSREM |
|---|---|---|
| ROE | 15.64% | 14.4% |
| ROCE | 16.18% | 14.81% |
| Net Margin | 11.52% | 13.35% |
| Operating Margin | 15.54% | 17.12% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | AMRUTANJAN | VENUSREM |
|---|---|---|
| Promoter Holding | 46.52% | 41.76% |
| FII Holding | 3.47%▲ 1.03 pp | 3.14%▲ 0.22 pp |
| DII Holding | 6.9%▼ 5.38 pp | 0.74%▼ 0.15 pp |
| Public Holding | 43.08%▲ 4.36 pp | 54.36%▼ 0.07 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMRUTAJAN HEALTH and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.